Location preference

Enter your country so we can show you products that are available for you.

News Release

Terumo Blood and Cell Technologies receives China registration for locally manufactured Trima Accel Automated Blood Collection System

Local manufacturing brings global apheresis experience and established quality capabilities to a platform used by blood centers in China for more than 20 years

SHANGHAI, China,  – Terumo Blood and Cell Technologies (Terumo BCT) today announced that its locally manufactured Trima Accel™ Automated Blood Collection System received the Medical Device Registration Certificate from China’s National Medical Products Administration.

The registration marks the first product milestone in Terumo BCT’s phased localization program announced in 2024 and advances the company’s “In China, for China” approach. It reflects Terumo BCT’s long-term commitment to investing in local capabilities that support customers and the evolving needs of China’s blood collection sector.

It comes as China continues to strengthen its blood supply capabilities and blood centers modernize their operations. National health authorities have identified growing clinical demand as well as seasonal, regional and blood-type-specific supply pressures.

“A resilient blood supply depends on the consistent collection of blood components,” said Takaharu Morimoto, vice president Asia Pacific and general manager Japan, Terumo BCT. “By manufacturing the Trima Accel system locally, we are combining more than six decades of global apheresis experience with established manufacturing capabilities and quality systems in China. This strengthens our ability to support customers locally while maintaining the quality and performance they expect from Terumo BCT.”

Local manufacturing of the Trima Accel system is supported by the expertise and quality systems of Terumo Medical Products (Hangzhou) Co., Ltd. (TMPH). TMPH is certified to ISO 13485 and has been recognized as a Zhejiang Good Manufacturing Practice Demonstration Enterprise. It also has successfully completed China GMP inspections.

The Trima Accel system automates the collection of blood components, including platelets. Together with Terumo BCT’s software, the system is part of the Trima Collection Smart Solution*, designed to help blood centers improve efficiency, strengthen oversight of collection activity and enable data-driven decision-making.

“Blood centers in China have relied on the Trima Accel system for more than 20 years,” said Clarence Chen, general manager, Terumo BCT China. “Local manufacturing builds on that foundation, bringing our technology, quality capabilities and customer support closer together as we continue to invest in the China market.”

More than 10,000 Trima Accel systems are installed in over 100 countries. Trima Accel is the first product milestone in Terumo BCT’s phased localization program in China. The company also plans to advance the localization of the Spectra Optia™ Apheresis System and disposable sets as the program continues.

*Trima Collection Smart Solution is the name used in China for the Trima Accel system together with Terumo BCT software.

All brand names are trademarks or registered trademarks owned by Terumo Corporation, its affiliates, or unrelated third parties. See TerumoBCT.com/Trademarks for details.

 

Click here for the Mandarin version of the press release. 


About Terumo Blood and Cell Technologies

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today.

Terumo Blood and Cell Technologies customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in more than 160 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.

We have global headquarters in Lakewood, Colorado, along with four regional headquarters, eight manufacturing sites and seven research and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.

Terumo BCT has served customers in China for more than 20 years.

To top